Pocket Program - CROI

CROI 2013 Session 26
11:00 85 Impact of Routine Laboratory Monitoring after
ART Initiation in 1206 HIV + African Children: The
5-Year Anti-Retroviral Research for Watoto Trial
Adeodata Kekitiinwa* 1 , A Cook 2 , K Nathoo 3 , P Mugyenyi 4 ,
P Nahirya-Ntege 5 , M Bwakura-Dangarembizi 3 , P Munderi 5 ,
P Musoke 6 , S Walker 2 , D Gibb 2 , and ARROW Trial Team
1 Baylor-Uganda/Paediatric Infectious Diseases Clin, Mulago;; 2 MRC
Clinical Trials Unit, London, UK;; 3 Univ of Zimbabwe, Harare;; 4 Joint
Clinical Res Ctr, Kampala, Uganda;; 5 MRC/UVRI Uganda Res Unit
on AIDS, Entebbe;; and 6 Makerere Univ, Kampala, Uganda
11:15 86 Randomized Comparison of Stopping vs
Continuing Cotrimoxazole Prophylaxis among
758 HIV + Children on Long-term ART:
The Anti-Retroviral Research for Watoto Trial
Mutsa Bwakura-Dangarembizi* 1 , L Kendall 2 , S Bakeera-Kitaka 3 ,
P Nahirya-Ntege 4 , R Keishanyu 5 , A Kekitiinwa 3 , E Natukunda 5 ,
S Walker 2 , D Gibb 2 , A Prendergast 2 , and ARROW Study Group
1 Univ of Zimbabwe, Harare;; 2 MRC Clinical Trials Unit, London,
UK;; 3 Baylor-Uganda, Paediatric Infectious Diseases Clin, Mulago
Hosp, Kampala;; 4 MRC/Uganda Res Unit on AIDS, Uganda Virus
Res Inst, Entebbe;; and 5 Joint Clinical Res Ctr, Kampala, Uganda
11:30 87 Selection of ARV Regimen Impacts Antimalarial
Pharmacokinetics and Treatment Outcomes in
HIV-Malaria Co-infected Children in Uganda
Norah Mwebaza* 1 , R Kajubi 1 , J Ssebuliba 1 , S Kiconco 1 , L Huang 2 ,
Q Gao 2 , A Kakuru 1 , J Achan 1 , F Aweeka 2 , and S Parikh 2,3
1 Makerere Univ, Kampala, Uganda;; 2 Univ of California, San Francisco,
US;; and 3 Yale Univ Sch of Publ Hlth and Med, New Haven, CT, US
11:45 88LB Comparison of Virologic and Immunologic
Outcomes between HIV + Ugandan Children
Randomized to Ritonavir-boosted Lopinavir
or NNRTI-based ART
Theodore Ruel* 1 , A Kakuru 2 , G Ikilezi 2 , F Mwangwa 2 , G Dorsey 1 ,
P Rosenthal 1 , E Charlebois 1 , D Havlir 1 , M Kamya 3 , and J Achan 3
1 Univ of California, San Francisco, US;; 2 Infectious Diseases Res
Collaboration, Kampala;; and 3 Makerere Univ, Kampala, Uganda
12:00 89LB A Novel Innate HIV-1 Neutralizing Protein
Isolated from Breast Milk
G Fouda, F Jaeger, J Amos, C Ho, K Anasti, T Ohashi, A Moseley,
H Erickson, M Alam, and Sallie Permar*
Duke Univ Med Ctr
k Tuesday, 10 am-12 n; Ballroom 1-2
Session 25–Oral Abstracts
North and South: Epidemiology and Engagement in
Care
Moderators:
Gottfried Hirnschall, WHO, Geneva, Switzerland
Manya Mangus, George Washington Univ, Washington, DC, US (invited)
10:00 90 HIV Prevalence and Awareness of Infection in
2008 and 2011 among MSM: 20 US Cities
Cyprian Wejnert*, B Le, J Zhu, T Finlayson, A Oster, A Smith,
G Paz-Bailey, for NHBS Study Group
CDC, Atlanta, GA, US
10:15 91 Age and Racial Disparities in Per-contact Risk
of HIV Seroconversion among MSM: US
Hyman Scott* 1,2 , E Vittinghoff 1 , and S Buchbinder
21 Univ of California, San Francisco, US and 2 San Francisco Dept of
Publ Hlth, CA, US
10:30 92 Determinants of Mortality and Loss to Follow-up
among Adult Patients in Pre-ART Care and on
ART: Rwanda
Chloe Teasdale* 1 , V Mugisha 1 , C Wang 1 ,
H Nuwagaba-Biribonwoha 1 , E Tayebwa 1 , E Ingabire 1 , P Ingabire 2 ,
M Lahuerta 1 , R Sahabo 1 , and E Abrams 1
1 Intl Ctr for AIDS Care and Treatment Prgms, Columbia Univ,
Mailman Sch of Publ Hlth, New York, NY, US and 2 Rwanda Ministry
of Hlth, Kigali
10:45 93 ART Initiation Substantially Improves Retention
among Patients Enrolling in Care: Lusaka, Zambia
M Li 1,2 , Brad Guffey* 1,3 , P Musonda 1,4 , I Sikazwe 5 , A Mwango 5 ,
B Chi 1,2 , and J Stringer 1,2
1 Ctr for Infectious Disease Res in Zambia, Lusaka;; 2 Univ of North
Carolina at Chapel Hill, US;; 3 Univ of Alabama at Birmingham, US;; 4 Univ
of East Anglia, Norwich, UK;; and 5 Zambian Ministry of Hlth, Lusaka
11:00 94 CD4 Count and Late Enrollment into HIV Care:
Comparison between 2006 and 2011 in 4
Sub-Saharan African Countries
Susie Hoffman* 1,2 , Y Wu 3 , W El-Sadr 1,3 , M Lahuerta 3 ,
H Nuwagaba-Biribonwoha 3 , V Mugisha 3 , M Hawken 3 , E Chuva 4 ,
D Nash 1,2,5 , B Elul 3 , and LSTART Team and Identifying Optimal
Models of HIV Care Collaboration
1 HIV Ctr for Clinical and Behavioral Studies at New York State
Psychiatric Inst and Columbia Univ, New York, US;; 2 Mailman Sch
of Publ Hlth, Columbia Univ, New York, NY, US;; 3 Intl Ctr for AIDS
Care and Treatment Prgms, Columbia Univ, Mailman Sch of Publ
Hlth, New York, NY, US;; 4 Ministry of Hlth, Maputo, Mozambique;;
and 5 CUNY Sch of Publ Hlth at Hunter Coll, New York, US
11:15 95LB Home Assessment and Initiation of ART following
HIV Self-Testing: A Cluster-Randomized Trial
to Improve Linkage to ART in Blantyre, Malawi
Peter MacPherson* 1,2 , D Lalloo1 , A Choko3 , J van Oosterhout2 ,
D Thindwa3 , E Webb4 , B Squire1 , S Makombe5 , R Hayes4 , and E Corbett3,4 1 2 Liverpool Sch of Tropical Med, UK;; Coll of Med, Univ of Malawi,
Blantyre;; 3Malawi-Liverpool-Wellcome Trust Clin Res Prgm,
Blantyre;; 4London Sch of Hygiene and Tropical Med, UK;; and 5HIV Dept, Ministry of Hlth, Lilongwe, Malawi
11:30 96 Population HIV Viral Load Estimate in Swaziland:
Assessing ART Program Effectiveness and
Transmission Potential
Jessica Justman* 1 , T Ellman2 , D Donnell3 , Y Duong4 , J Reed5 ,
G Bicego4 , P Ehrenkranz6 , L Wang3 , N Bock4 , and R Nkambule7 1Intl Ctr for AIDS Care and Treatment Prgms, Columbia Univ,
Mailman Sch of Publ Hlth, New York, NY, US;; 2Columbia Univ Med
Ctr, New York, NY, US;; 3Fred Hutchinson Cancer Res Ctr, Seattle, WA,
US;; 4CDC, Atlanta, GA, US;; 5State Dept, Washington, DC, US;; 6CDC, Mbabane, Swaziland;; and 7Ministry of Hlth, Mbabane, Swaziland
11:45 97 Molecular Characterization of the Source of New
Infections in a High-risk Population in Uganda:
Implications for Test and Treat as Prevention
Chris Parry* 1 , J Levin1 , J Nazziwa1 , G Asiki1 , J Mpendo2 , H Njai1 ,
J Seeley1 , A Kamali1 , L Nieslen3 , and PK Kaleebu1 1 2 MRC/UVRI Research Unit on AIDS, Entebbe;; UVRI-IAVI HIV
Vaccine Prgm, Entebbe;; and 3IAVI, Entebbe, Uganda
k Tuesday, 10 am-12:15 pm; Hall B1
Session 26–Oral Abstracts
ART: New Agents and New Insights
Moderators:
Roger Paredes, IrsiCaixa Inst for AIDS Res, Badalona, Catalonia, Spain
Raymond Schinazi, Emory Univ and VAMC, Atlanta, GA, US
10:00 98 Role of APOBEC3G in the Emergence of M184I
in vivo
W Shao 1 , E Wilson 2 , S Hill 2 , J Spindler 2 , R Dewar 1 , C Rehm 3 ,
M Sneller 3 , M Kearney 2 , J Coffin 4 , and Frank Maldarelli* 2
1 SAIC-Frederick, NCI-Frederick, MD, US;; 2 NCI, Frederick Natl
Lab for Cancer Res, MD, US;; 3 NIAID, NIH, Bethesda, MD, US;;
and 4 Tufts Univ, Boston, MA, US
10:15 99LB Comparative Study of Tenofovir Alafenamide
vs Tenofovir Disoproxil Fumarate, Each with
Elvitegravir, Cobicistat, and Emtricitabine,
for HIV Treatment
Andrew Zolopa* 1 , R Ortiz 2 , P Sax 3 , I Brar 4 , R Elion 5 , H Wang 6 ,
C Callebaut 6 , S Ramanathan 6 , M Fordyce 6 , and S McCallister 6
1 Stanford Univ, Palo Alto, CA, US;; 2 Orlando Imm Ctr, FL, US;;
3 Brigham and Womens Hosp, Harvard Med Sch, Boston MA, US;;
4 Henry Ford Hosp, Detroit, MI, US;; 5 George Washington Univ
Hosp, Washington, DC, US;; and 6 Gilead Sci, Foster City, CA, US
10:30 100 Safety and Antiviral Activity of MK-1439, a
Novel NNRTI, in Treatment-naïve HIV + Patients
Matt Anderson* 1 , J Gilmartin 1 , M Robberechts 1 , I De Lepeleire 1 ,
E Tetteh 1 , Y Guo 1 , D Schurman 2 , F Wagner 3 , J Wagner 1 ,
and J Butterton 1
1 Merck Sharp & Dohme, Corp, Whitehouse Station, NJ, US;; 2 Charite
Universitatsmedizin, Berlin, Germany;; and 3 Charite Res Org,
Berlin, Germany
10:45 101 Mechanism by which K103N in HIV-1 Reverse
Transcriptase Confers Efavirenz Resistance
Revealed by Single-molecule Fluorescence
Spectroscopy
Grant Schauer*, N Sluis-Cremer, and S Leuba
Univ of Pittsburgh Sch of Med, PA, US
Program 11
Tuesday
March 5 Oral Sessions